Rozanolixizumab, sold under the brand name Rystiggo, is a monoclonal antibody used for the treatment of myasthenia gravis.

It is a humanized and chimeric monoclonal antibody; and is a neonatal Fc receptor blocker.

Routes of administration Subcutaneous

The most common adverse reactions include headache, infections, diarrhea, pyrexia, hypersensitivity reactions, and nausea.

Rozanolixizumab is indicated for the treatment of generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive.

Leave a Reply

Your email address will not be published. Required fields are marked *